UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Adversarial synthesis learning enables segmentation without target modality ground truth

2018 IEEE 15th International Symposium on Biomedical Imaging (ISBI 2018), 2018, p.1217-1220

2018

Volltextzugriff (PDF)

Splenomegaly Segmentation on Multi-Modal MRI Using Deep Convolutional Networks

IEEE transactions on medical imaging, 2019-05, Vol.38 (5), p.1185-1196

2019

Volltextzugriff (PDF)

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

Blood, 2017-10, Vol.130 (15), p.1768-1771

2017

Volltextzugriff (PDF)

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis

Haematologica (Roma), 2017-02, Vol.102 (2), p.327-335

2017

Volltextzugriff (PDF)

Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma

Journal of clinical oncology, 2007-07, Vol.25 (19), p.2764-2769

2007

Volltextzugriff (PDF)

P1046: TREATMENT COMPARISON OF HYDROXYUREA VS RUXOLITINIB IN ESSENTIAL THROMBOCYTHEMIA (ET): A MATCHED COHORT ANALYSIS

HemaSphere, 2023-08, Vol.7 (S3), p.e94647fb-n/a

2023

Volltextzugriff (PDF)

Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched‐cohort analysis

EJHaem, 2024-08, Vol.5 (4), p.778-783

2024

Volltextzugriff (PDF)

SynSeg-Net: Synthetic Segmentation Without Target Modality Ground Truth

IEEE transactions on medical imaging, 2019-04, Vol.38 (4), p.1016-1025

2019

Volltextzugriff (PDF)

Abstract CT252: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment-Naïve Myelofibrosis

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT252-CT252

2021

Volltextzugriff (PDF)

Abstract CT253: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Parsaclisib Plus Ruxolitinib in Patients with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT253-CT253

2021

Volltextzugriff (PDF)

In vitro and In vivo Characterization of MDX-1401 for Therapy of Malignant Lymphoma

Clinical cancer research, 2009-05, Vol.15 (10), p.3376-3383

2009

Volltextzugriff (PDF)

A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naïve myelofibrosis

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS7058-TPS7058

2021

Volltextzugriff (PDF)

Building a Generic Big Data Analytics Framework for E-commerce in Developing Countries

International journal of digital information and wireless communications, 2018-10, Vol.8 (4), p.280-287

Assad, Christina Albert Rayed

2018

Volltextzugriff (PDF)

Targeting the PI3K pathway in myeloproliferative neoplasms

Expert review of anticancer therapy, 2022-08, Vol.22 (8), p.835-843

2022

Volltextzugriff (PDF)

Robust Multicontrast MRI Spleen Segmentation for Splenomegaly Using Multi-Atlas Segmentation

IEEE transactions on biomedical engineering, 2018-02, Vol.65 (2), p.336-343

2018

Volltextzugriff (PDF)

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors

The oncologist (Dayton, Ohio), 2019-01, Vol.24 (1), p.14-e10

2019

Volltextzugriff (PDF)

MPN-556 Treatment Comparison of Hydroxyurea vs Ruxolitinib in Essential Thrombocythemia (ET): A Matched Cohort Analysis

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S403-S403

2023

Volltextzugriff (PDF)

POSTER: MPN-556 Treatment Comparison of Hydroxyurea vs Ruxolitinib in Essential Thrombocythemia (ET): A Matched Cohort Analysis

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S192-S192

2023

Volltextzugriff (PDF)

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase

Blood, 2018-11, Vol.132 (Supplement 1), p.555-555

2018

Volltextzugriff (PDF)

Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

Blood, 2022-11, Vol.140 (Supplement 1), p.579-582

2022

Volltextzugriff (PDF)

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Blood, 2021-11, Vol.138 (Supplement 1), p.3647-3647

2021

Volltextzugriff (PDF)

Stroke Treatment Academic Industry Roundtable (STAIR) Recommendations for Maximizing the Use of Intravenous Thrombolytics and Expanding Treatment Options With Intra-arterial and Neuroprotective Therapies

Stroke (1970), 2011-09, Vol.42 (9), p.2645-2650

2011

Volltextzugriff (PDF)

Abstract CT162: Addition of parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT162-CT162

2021

Volltextzugriff (PDF)

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations

Blood, 2022-11, Vol.140 (Supplement 1), p.6117-6118

2022

Volltextzugriff (PDF)

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

Blood, 2018-11, Vol.132 (Supplement 1), p.353-353

2018

Volltextzugriff (PDF)

1 – 25 von 163

Suche als RSS-Feed

Aktive Filter

ThemaCloud Computing

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(158)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(163)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(33)
Network Hardware
(31)
Communications Engineering / Telecommunications
(30)
Health & Safety Aspects Of Computing
(30)
Life Sciences & Biomedicine
(28)
Humans
(19)
Fog Computing
(10)
Male
(10)
Technology
(9)
Computer Science
(8)
Engineering
(7)
Biological And Medical Sciences
(6)
Female
(6)
Ruxolitinib
(6)
Aged
(5)
Big Data
(5)
Engineering, Biomedical
(5)
General & Internal Medicine
(5)
Hematology
(5)
Image Segmentation
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Adversarial synthesis learning enables segmentation without target modality ground truth

Splenomegaly Segmentation on Multi-Modal MRI Using Deep Convolutional Networks

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis

Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma

P1046: TREATMENT COMPARISON OF HYDROXYUREA VS RUXOLITINIB IN ESSENTIAL THROMBOCYTHEMIA (ET): A MATCHED COHORT ANALYSIS

Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched‐cohort analysis

SynSeg-Net: Synthetic Segmentation Without Target Modality Ground Truth

Abstract CT252: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment-Naïve Myelofibrosis

Abstract CT253: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Parsaclisib Plus Ruxolitinib in Patients with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

In vitro and In vivo Characterization of MDX-1401 for Therapy of Malignant Lymphoma

A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naïve myelofibrosis

Building a Generic Big Data Analytics Framework for E-commerce in Developing Countries

Targeting the PI3K pathway in myeloproliferative neoplasms

Robust Multicontrast MRI Spleen Segmentation for Splenomegaly Using Multi-Atlas Segmentation

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors

MPN-556 Treatment Comparison of Hydroxyurea vs Ruxolitinib in Essential Thrombocythemia (ET): A Matched Cohort Analysis

POSTER: MPN-556 Treatment Comparison of Hydroxyurea vs Ruxolitinib in Essential Thrombocythemia (ET): A Matched Cohort Analysis

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase

Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Stroke Treatment Academic Industry Roundtable (STAIR) Recommendations for Maximizing the Use of Intravenous Thrombolytics and Expanding Treatment Options With Intra-arterial and Neuroprotective Therapies

Abstract CT162: Addition of parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

Aktive Filter

Suchergebnisse filtern